Global Oligonucleotide Therapeutics Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2024-2030

Publication ID:

PB506248755

Publication Date:

June 10, 2024

Pages:

132

Publisher:

MRRPB5

Countries:

Global [1]

USD 5,900.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

Many pharmaceutical companies were conducting research on oligonucleotide therapy, which employs chemically synthesized nucleotide-like small molecule drugs with potential specificity similar to that of therapeutic antibodies.
Although several types of oligonucleotide therapies exist, five of them are compared here, including the ones targeting nucleic acids (such as mRNA) or proteins, as well as others intended for stimulation of the immune system. DDS is generally used with oligonucleotide therapy, as it is difficult for these molecules to penetrate cell membrane when administered on their own.
The global market for Oligonucleotide Therapeutics was estimated to be worth US$ 3678.1 million in 2023 and is forecast to a readjusted size of US$ 10970 million by 2030 with a CAGR of 16.7% during the forecast period 2024-2030.
Biogen is the industry's biggest player, with more than 76 percent of 2018 revenue, followed by Sarepta Therapeutics and Jazz Pharmaceuticals, with 13.35 percent and 6.63 percent, respectively. North America and Europe are the most important regions, accounting for more than 80 percent of the combined income.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Oligonucleotide Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyse their position in the current marketplace, and make informed business decisions regarding Oligonucleotide Therapeutics.
The Oligonucleotide Therapeutics market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Oligonucleotide Therapeutics market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Oligonucleotide Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, product type, application, and regions.
Market Segmentation
By Company
Biogen
Sarepta Therapeutics
Jazz Pharmaceuticals
Bausch & Lomb
Alnylam Pharmaceuticals
Dynavax Technologies
Kastle therapeutics
Akcea Therapeutics
Segment by Type
Antisense Oligonucleotide
Aptamer
Other
Segment by Application
Neuromuscular Diseases
ATTR
Hepatic VOD
Other
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
India
Southeast Asia
Australia
Rest of Asia-Pacific
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of Middle East & Africa
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on.
Chapter 2: Revenue of Oligonucleotide Therapeutics in global and regional level.
Chapter 3: Detailed analysis of Oligonucleotide Therapeutics company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Oligonucleotide Therapeutics revenue, gross margin, and recent development, etc.
Chapter 5: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
Chapter 8: Europe by Type, by Application and by country, revenue for each segment.
Chapter 9: Asia Pacific by Type, by Application and by region, revenue for each segment.
Chapter 10: Latin America by Type, by Application and by country, revenue for each segment.
Chapter 11: Middle East and Africa, by Type, by Application and by country, revenue for each segment.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: Research Findings and Conclusion

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Study Coverage
1.1 Oligonucleotide Therapeutics Product Introduction
1.2 Market by Type
1.2.1 Global Oligonucleotide Therapeutics Market Size Growth Rate by Type (2019 VS 2023 VS 2030)
1.2.2 Antisense Oligonucleotide
1.2.3 Aptamer
1.2.4 Other
1.3 Market by Application
1.3.1 Global Oligonucleotide Therapeutics Market Size Growth Rate by Application (2019 VS 2023 VS 2030)
1.3.2 Neuromuscular Diseases
1.3.3 ATTR
1.3.4 Hepatic VOD
1.3.5 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Oligonucleotide Therapeutics Market Size Estimates and Forecasts
2.2 Oligonucleotide Therapeutics Market Size by Region: 2023 Versus 2030
2.2.1 Global Oligonucleotide Therapeutics Revenue by Region: 2019-2024
2.2.2 Global Oligonucleotide Therapeutics Revenue Forecast by Region (2025-2030)
2.2.3 Global Oligonucleotide Therapeutics Revenue Market Share by Region (2019-2030)
3 Global Oligonucleotide Therapeutics by Company
3.1 Global Oligonucleotide Therapeutics Revenue by Company (2019-2024)
3.2 Global Oligonucleotide Therapeutics Revenue Share by Company (2019-2024)
3.3 Competitive Landscape
3.3.1 Key Oligonucleotide Therapeutics Companies around the World: Ranking by Revenue
3.3.2 Global Oligonucleotide Therapeutics Market Concentration Ratio (CR5 and HHI) & (2019-2024)
3.3.3 Global Oligonucleotide Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.4 Global Oligonucleotide Therapeutics Companies Headquarters & Product Type
3.4.1 Oligonucleotide Therapeutics Companies Headquarters
3.4.2 Global Oligonucleotide Therapeutics Companies Product & Service
3.4.3 Date of International Companies Enter into Oligonucleotide Therapeutics Market
3.5 Global Oligonucleotide Therapeutics Mergers & Acquisitions, Expansion Plans
4 Company Profiles
4.1 Biogen
4.1.1 Biogen Company Information
4.1.2 Biogen Description, Business Overview
4.1.3 Biogen Oligonucleotide Therapeutics Products Offered
4.1.4 Biogen Oligonucleotide Therapeutics Revenue and Gross Margin (2019-2024)
4.1.5 Biogen Oligonucleotide Therapeutics Revenue by Product in 2023
4.1.6 Biogen Oligonucleotide Therapeutics Revenue by Application in 2023
4.1.7 Biogen Oligonucleotide Therapeutics Revenue by Geographic Area in 2023
4.1.8 Biogen Recent Developments
4.2 Sarepta Therapeutics
4.2.1 Sarepta Therapeutics Company Information
4.2.2 Sarepta Therapeutics Description, Business Overview
4.2.3 Sarepta Therapeutics Oligonucleotide Therapeutics Products Offered
4.2.4 Sarepta Therapeutics Oligonucleotide Therapeutics Revenue and Gross Margin (2019-2024)
4.2.5 Sarepta Therapeutics Oligonucleotide Therapeutics Revenue by Product in 2023
4.2.6 Sarepta Therapeutics Oligonucleotide Therapeutics Revenue by Application in 2023
4.2.7 Sarepta Therapeutics Oligonucleotide Therapeutics Revenue by Geographic Area in 2023
4.2.8 Sarepta Therapeutics Recent Developments
4.3 Jazz Pharmaceuticals
4.3.1 Jazz Pharmaceuticals Company Information
4.3.2 Jazz Pharmaceuticals Description, Business Overview
4.3.3 Jazz Pharmaceuticals Oligonucleotide Therapeutics Products Offered
4.3.4 Jazz Pharmaceuticals Oligonucleotide Therapeutics Revenue and Gross Margin (2019-2024)
4.3.5 Jazz Pharmaceuticals Oligonucleotide Therapeutics Revenue by Product in 2023
4.3.6 Jazz Pharmaceuticals Oligonucleotide Therapeutics Revenue by Application in 2023
4.3.7 Jazz Pharmaceuticals Oligonucleotide Therapeutics Revenue by Geographic Area in 2023
4.3.8 Jazz Pharmaceuticals Recent Developments
4.4 Bausch & Lomb
4.4.1 Bausch & Lomb Company Information
4.4.2 Bausch & Lomb Description, Business Overview
4.4.3 Bausch & Lomb Oligonucleotide Therapeutics Products Offered
4.4.4 Bausch & Lomb Oligonucleotide Therapeutics Revenue and Gross Margin (2019-2024)
4.4.5 Bausch & Lomb Oligonucleotide Therapeutics Revenue by Product in 2023
4.4.6 Bausch & Lomb Oligonucleotide Therapeutics Revenue by Application in 2023
4.4.7 Bausch & Lomb Oligonucleotide Therapeutics Revenue by Geographic Area in 2023
4.4.8 Bausch & Lomb Recent Developments
4.5 Alnylam Pharmaceuticals
4.5.1 Alnylam Pharmaceuticals Company Information
4.5.2 Alnylam Pharmaceuticals Description, Business Overview
4.5.3 Alnylam Pharmaceuticals Oligonucleotide Therapeutics Products Offered
4.5.4 Alnylam Pharmaceuticals Oligonucleotide Therapeutics Revenue and Gross Margin (2019-2024)
4.5.5 Alnylam Pharmaceuticals Oligonucleotide Therapeutics Revenue by Product in 2023
4.5.6 Alnylam Pharmaceuticals Oligonucleotide Therapeutics Revenue by Application in 2023
4.5.7 Alnylam Pharmaceuticals Oligonucleotide Therapeutics Revenue by Geographic Area in 2023
4.5.8 Alnylam Pharmaceuticals Recent Developments
4.6 Dynavax Technologies
4.6.1 Dynavax Technologies Company Information
4.6.2 Dynavax Technologies Description, Business Overview
4.6.3 Dynavax Technologies Oligonucleotide Therapeutics Products Offered
4.6.4 Dynavax Technologies Oligonucleotide Therapeutics Revenue and Gross Margin (2019-2024)
4.6.5 Dynavax Technologies Oligonucleotide Therapeutics Revenue by Product in 2023
4.6.6 Dynavax Technologies Oligonucleotide Therapeutics Revenue by Application in 2023
4.6.7 Dynavax Technologies Oligonucleotide Therapeutics Revenue by Geographic Area in 2023
4.6.8 Dynavax Technologies Recent Development
4.7 Kastle therapeutics
4.7.1 Kastle therapeutics Company Information
4.7.2 Kastle therapeutics Description, Business Overview
4.7.3 Kastle therapeutics Oligonucleotide Therapeutics Products Offered
4.7.4 Kastle therapeutics Oligonucleotide Therapeutics Revenue and Gross Margin (2019-2024)
4.7.5 Kastle therapeutics Oligonucleotide Therapeutics Revenue by Product in 2023
4.7.6 Kastle therapeutics Oligonucleotide Therapeutics Revenue by Application in 2023
4.7.7 Kastle therapeutics Oligonucleotide Therapeutics Revenue by Geographic Area in 2023
4.7.8 Kastle therapeutics Recent Development
4.8 Akcea Therapeutics
4.8.1 Akcea Therapeutics Company Information
4.8.2 Akcea Therapeutics Description, Business Overview
4.8.3 Akcea Therapeutics Oligonucleotide Therapeutics Products Offered
4.8.4 Akcea Therapeutics Oligonucleotide Therapeutics Revenue and Gross Margin (2019-2024)
4.8.5 Akcea Therapeutics Oligonucleotide Therapeutics Revenue by Product in 2023
4.8.6 Akcea Therapeutics Oligonucleotide Therapeutics Revenue by Application in 2023
4.8.7 Akcea Therapeutics Oligonucleotide Therapeutics Revenue by Geographic Area in 2023
4.8.8 Akcea Therapeutics Recent Development
5 Breakdown Data by Type
5.1 Global Oligonucleotide Therapeutics Revenue by Type (2019-2024)
5.2 Global Oligonucleotide Therapeutics Revenue Forecast by Type (2025-2030)
5.3 Oligonucleotide Therapeutics Revenue Market Share by Type (2019-2030)
6 Breakdown Data by Application
6.1 Global Oligonucleotide Therapeutics Revenue by Application (2019-2024)
6.2 Global Oligonucleotide Therapeutics Revenue Forecast by Application (2025-2030)
6.3 Oligonucleotide Therapeutics Revenue Market Share by Application (2019-2030)
7 North America
7.1 North America Oligonucleotide Therapeutics Market Size YoY Growth 2019-2030
7.2 North America Oligonucleotide Therapeutics Market Facts & Figures by Country (2019-2030)
7.3 North America Oligonucleotide Therapeutics Revenue by Type (2019-2024)
7.4 North America Oligonucleotide Therapeutics Revenue by Application (2019-2024)
8 Asia-Pacific
8.1 Asia-Pacific Oligonucleotide Therapeutics Market Size YoY Growth 2019-2030
8.2 Asia-Pacific Oligonucleotide Therapeutics Market Facts & Figures by Region (2019-2030)
8.3 Asia-Pacific Oligonucleotide Therapeutics Revenue by Type (2019-2024)
8.4 Asia-Pacific Oligonucleotide Therapeutics Revenue by Application (2019-2024)
9 Europe
9.1 Europe Oligonucleotide Therapeutics Market Size YoY Growth 2019-2030
9.2 Europe Oligonucleotide Therapeutics Market Facts & Figures by Country (2019-2030)
9.3 Europe Oligonucleotide Therapeutics Revenue by Type (2019-2024)
9.4 Europe Oligonucleotide Therapeutics Revenue by Application (2019-2024)
10 Latin America
10.1 Latin America Oligonucleotide Therapeutics Market Size YoY Growth 2019-2030
10.2 Latin America Oligonucleotide Therapeutics Market Facts & Figures by Country (2019-2030)
10.3 Latin America Oligonucleotide Therapeutics Revenue by Type (2019-2024)
10.4 Latin America Oligonucleotide Therapeutics Revenue by Application (2019-2024)
11 Middle East and Africa
11.1 Middle East and Africa Oligonucleotide Therapeutics Market Size YoY Growth 2019-2030
11.2 Middle East and Africa Oligonucleotide Therapeutics Market Facts & Figures by Country (2019-2030)
11.3 Middle East and Africa Oligonucleotide Therapeutics Revenue by Type (2019-2024)
11.4 Middle East and Africa Oligonucleotide Therapeutics Revenue by Application (2019-2024)
12 Supply Chain and Sales Channel Analysis
12.1 Oligonucleotide Therapeutics Supply Chain Analysis
12.2 Oligonucleotide Therapeutics Key Raw Materials and Upstream Suppliers
12.3 Oligonucleotide Therapeutics Clients Analysis
12.4 Oligonucleotide Therapeutics Sales Channel and Sales Model Analysis
12.4.1 Oligonucleotide Therapeutics Distribution Channel Analysis: Indirect Sales VS Direct Sales
12.4.2 Oligonucleotide Therapeutics Distribution Channel Analysis: Online Sales VS Offline Sales
12.4.3 Oligonucleotide Therapeutics Distributors
13 Market Dynamics
13.1 Oligonucleotide Therapeutics Industry Trends
13.2 Oligonucleotide Therapeutics Market Drivers
13.3 Oligonucleotide Therapeutics Market Challenges
13.4 Oligonucleotide Therapeutics Market Restraints
14 Research Findings and Conclusion
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

Companies Mentioned:

Biogen
Sarepta Therapeutics
Jazz Pharmaceuticals
Bausch & Lomb
Alnylam Pharmaceuticals
Dynavax Technologies
Kastle therapeutics
Akcea Therapeutics

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂